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Abstract
Purpose PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in patients with heart failure and
reduced ejection fraction (HF-REF). How widely applicable sacubitril/valsartan treatment is in unselected patients with HF-REF
is not known. We examined eligibility of patients with HF-REF for treatment with sacubitril/valsartan, according to the criteria
used in PARADIGM-HF, in the Swedish Heart Failure Registry (SwedeHF).
Methods Patients were considered potentially eligible if they were not hospitalized, had symptoms (NYHA class II–IV) and a
reduced LVEF (≤ 40%), and were prescribed an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker
(ARB) at a dose equivalent to enalapril ≥ 10 mg daily. In these patients, we evaluated further eligibility according to the main
additional PARADIGM-HF inclusion criteria.
Results Of 12,866 outpatients in NYHA functional class II–IV with an LVEF ≤ 40%, 9577 were prescribed at least 10 mg of
enalapril (or equivalent) daily. Complete additional data were available for 3099 of these patients (32.4%) and of them 75.5%
were potentially eligible for treatment with sacubitril/valsartan. The most common reason for ineligibility was a low natriuretic
peptide level (n = 462, 14.9%). Only a small proportion of patients were ineligible due to low eGFR or serum potassium level.
Because only 78% of patients were taking ≥ 10 mg enalapril or equivalent daily, only 58.9% of all patients (75.5% of 78%) were
eligible for sacubitril/valsartan.
Conclusions Between 34 and 76% of symptomatic patients with HF-REF in a ‘real world’ population are eligible for treatment
with sacubitril/valsartan, depending on background ACEI/ARB dose. The most common reason for ineligibility is a low
natriuretic peptide level.
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Introduction
The angiotensin receptor neprilysin inhibitor (ARNI)
sacubitril/valsartan combines an angiotensin receptor blocker
(ARB) with a neprilysin inhibitor. The Prospective compari-
son of ARNI with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure trial (PARADIGM-
HF) demonstrated the superiority of the sacubitril/valsartan
(formerly known as LCZ696) over the angiotensin-
converting enzyme inhibitor (ACEI) enalapril in patients with
heart failure and reduced ejection fraction (HF-REF) [1]. In
PARADIGM-HF, sacubitril/valsartan reduced the risk of the
primary composite outcome of cardiovascular death or heart
failure hospitalization by 20%, each of the components of that
endpoint by a similar amount and all-cause death by 16% [1].
As a result, international guidelines now recommend the use
of sacubitril/valsartan as a preferred alternative to an ACEI or
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ARB [2, 3]. How widely applicable sacubitril/valsartan treat-
ment is in unselected patients with HF-REF is uncertain. We
used the Swedish Heart Failure Registry (SwedeHF) to exam-
ine eligibility of patients for sacubitril/valsartan in an unselect-
ed nationwide cohort. We identified individuals fulfilling the
main inclusion criteria for the PARADIGM-HF trial, i.e., am-
bulatory patients with persisting symptoms (NYHA class II–
IV), low ejection fraction (EF) (< 40%), and elevated natri-
uretic peptides, despite treatment with an ACEI or an ARB
(scenario 1). To be enrolled in the PARADIGM-HF active
run-in phase, patients had to be treated with a dose of ACE
inhibitor or ARB equivalent to enalapril 10 mg daily—we
further identified the subset of patients in SwedeHF treated
in this way (scenario 2). Finally, as patients had to tolerate
up-titration to a daily dose of 20mg enalapril during the active
run in, we also identified the proportion of patients in
SwedeHF taking a dose of ACE inhibitor or ARB equivalent
to this dose of enalapril (scenario 3).
Methods
Patients
Patients with heart failure included in SwedeHF between
July 2005 and December 2012 were studied. This nationwide
internet-based registry has been described in detail [4].
Patients are included in the registry based upon a clinical
diagnosis of heart failure and registered at discharge from
hospital or following an outpatient visit. Data on over 100
primary and derived variables are collected, including clinical
findings, laboratory measurements, and medications. Left
ventricular EF is reported in the registry as less than 30%,
30–39%, 40–49%, and 50% or greater. For this study, we
included only patients with an EF < 40%, and only the most
recent patient encounter was considered.
Eligibility for Sacubitril/Valsartan
The entry criteria for PARADIGM-HFwere used to determine
eligibility status for each patient [5]. Patients were considered
potentially eligible and included in the denominator in this
study if they were not hospitalized (because only ambulatory
patients were included in PARADIGM-HF; potentially eligi-
ble patients in both an outpatient and inpatient setting are
shown in Supplementary Table 1) and had symptoms
(NYHA functional class II–IV) and a low EF (< 40%) and
were prescribed an ACEI or an ARB at a dose equivalent to
enalapril 10 mg daily. The dose equivalents for these analyses
were defined PARADIGM-HF inclusion criteria [5].
In these patients, we evaluated further eligibility in relation
to the main additional PARADIGM-HF inclusion criteria, i.e.,
plasma B-type natriuretic peptide (BNP) ≥ 150 pg/ml (or N-
terminal pro-BNP [NT-proBNP] ≥ 600 pg/ml) or, in patients
hospitalized for HF in the preceding 12 months, BNP ≥
100 pg/ml or NT-proBNP ≥ 400 pg/ml; and exclusion criteria,
i.e., systolic blood pressure (SBP) < 100 mmHg, serum potas-
sium concentration > 5.2 mmol/l, or an estimated glomerular
filtration rate (eGFR) < 30ml/min/1.73 m2. For the main anal-
yses, we only included patients with complete data entries for
these inclusion and exclusion criteria. In a consistency analy-
sis, missing data were imputed by multivariate imputation
using chained equations. The extent of missing data is shown
in Table 2 of the Supplementary Appendix.
Background ACE Inhibitor Dose
In PARADIGM-HF, patients had to be treated with an ACE
inhibitor or an ARB at a dose equivalent to enalapril 10 mg/
day for at least 4 weeks before the screening visit and then
entered an active run-in phase where they received open-label
enalapril which was titrated to a dose of 10 mg bid over a
period of 3 to 5 weeks. Patients tolerating enalapril 10 mg
bid were then started on sacubitril/valsartan 49/51 mg bid,
which, if tolerated, was increased to a dose of 97/103 mg
bid after 1–2 weeks. If tolerated, sacubitril/valsartan 97/
103 mg bid was continued for a further 2–4 weeks, at which
point patients were randomized to enalapril 10 mg bid or
sacubitril/valsartan 97/103 mg bid. At each step, during the
two run-in periods, patients had to demonstrate satisfactory
renal function and serum potassium concentration, as well as
a systolic blood pressure before randomization of at least
95 mmHg and no symptoms of hypotension. For this reason,
we did separate analyses of otherwise eligible patients de-
pending on whether they were on a background ACE
inhibitor/ARB dose equivalent to 10 mg daily and 20 mg
daily.
Ethical Considerations
Establishment of SwedeHF, and the present analysis, was ap-
proved by a multisite ethics committee. Patients in Sweden are
informed of the intent to include their data in the national
registry and may choose to opt out of this.
Statistical Analysis
For baseline characteristics, categorical data are presented as
numbers and percentages and parametric data as mean and
standard deviation (medians and interquartile ranges are used
for data that are not normally distributed).
Continuous variables were modeled with linear regression
and dichotomous variables were imputed via logistic regres-
sion. In sensitivity analyses to avoid bias from data not miss-
ing at random, multiple imputation was used to handle miss-
ing data.
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We considered a two-sided p value < 0.05 as significant.
All analyses were conducted using Stata version 14.1
(StataCorp LP, College Station, Texas).
Results
Baseline Characteristics
We studied 51,060 patients included in SwedeHF. The most
recent patient encounter was as an outpatient in 22,822 pa-
tients (potentially eligible patients in both an outpatient and
inpatient setting are shown in Supplementary Table 1). Of
these, 74 were excluded because of death on the day of their
visit, a further 8512 because of an EF ≥ 40%, and among the
remainder, 1370 were excluded because they were NYHA
functional class I. This left 12,866 patients in NYHA func-
tional class II–IV with an EF < 40%, i.e., potentially eligible
for treatment with sacubitril/valsartan; their baseline charac-
teristics are shown in Table 1.
Of these 12,866 patients, 3963 (31%) had complete data
with respect to the PARADIGM-HF inclusion/exclusion
criteria examined. Data were missing for BNP in 12,007 pa-
tients, NT-proBNP in 7838 (both natriuretic peptides were
missing in 6998 patients), potassium in 3629, creatinine in
1687, and systolic blood pressure in 251 patients.
Scenario 1: Eligibility of Patients Regardless
of Background ACE Inhibitor or ARB Dose
As stated above, among the 12,866 patients with symptomatic
HF-REF taking no or any dose of ACEI/ARB and potentially
eligible for treatment with sacubitril/valsartan, complete data
based on the PARADIGM-HF inclusion and exclusion criteria
were available for 3963 (31%) patients. Of these 3963 pa-
tients, 1032 (26%) were ineligible for treatment with
sacubitril/valsartan, i.e., 74% were eligible for treatment
(Fig. 1a). The most common reason for ineligibility was a
low natriuretic peptide level (n = 543, 13.7% of 3963 eligible
patients with complete data), followed by a low systolic blood
pressure (n = 359, 9.1%). Only a small proportion of patients
were ineligible due to a low eGFR (n = 143, 3.6%) or high
serum potassium level (n = 55, 1.4%).
A sensitivity analysis imputing missing values (increasing
the number of patients eligible for analysis to 8903) estimated
that 26% of patients were ineligible for treatment, i.e., 74%
were eligible for treatment.
Scenario 2: Eligibility of Patients Prescribed at Least
10 Mg Enalapril Daily, or Equivalent
Among the 9577 (74.4%) patients with symptomatic systolic
heart failure taking at least 10 mg of enalapril (or equivalent)
daily, and potentially eligible for treatment with sacubitril/
valsartan, complete data based on the PARADIGM-HF inclu-
sion and exclusion criteria were available for 3099 (32.4%)
patients. Of these 3099 patients, 759 (24.5%) were ineligible
for treatment with sacubitril/valsartan, i.e., 75.5% were poten-
tially eligible for treatment (Fig. 1b). The most common rea-
son for ineligibility was a low natriuretic peptide level (n =
462, 14.9% of 3099 eligible patients with complete data),
followed by a low systolic blood pressure (n = 245, 7.9%).
Only a small proportion of patients were ineligible due to a
low eGFR (n = 55, 1.8%) or a high serum potassium level
(n = 42, 1.4%).
A sensitivity analysis imputing missing values (n = 6478)
estimated that 24.54% of patients were ineligible for treat-
ment, i.e., 75.5% were potentially eligible for treatment with
sacubitril/valsartan.
Because 3099 of 3963 (78.2%) of patients were taking ≥
10 mg enalapril or equivalent daily, only 59.0% of all patients
(75.5% of 78.2%) were eligible for sacubitril/valsartan. The
equivalent figure using the imputed dataset was 52.44%
(75.5% of 72.8%).
Scenario 3: Eligibility of Patients Prescribed at Least
20 Mg Enalapril Daily, or Equivalent
Among the 6439 patients with symptomatic systolic heart
failure taking at least 20 mg of enalapril (or equivalent)
daily, and potentially eligible for treatment with sacubitril/
valsartan, complete data based on the PARADIGM-HF in-
clusion and exclusion criteria were available for 2168
(33.7%) patients. Of these 2168 patients, 489 (22.6%) were
ineligible for treatment with sacubitril/valsartan, i.e., 77.4%
were potentially eligible for treatment (Fig. 1c). The most
common reason for ineligibility was a low natriuretic pep-
tide level (n = 349, 16.1% of 2168 eligible patients with
complete data) followed by a low systolic blood pressure
(n = 127, 5.9%). Only a small proportion of patients were
ineligible due to a low eGFR (n = 18, 0.8%) or a high serum
potassium level (n = 26, 1.2%).
A sensitivity analysis imputing missing values (n = 4271)
estimated that 22.6% of patients were ineligible for treatment,
i.e., 77.4% were potentially eligible for treatment.
Because only 54.7% of patients were taking ≥ 20 mg enal-
april or equivalent daily, only 42.3% of all patients (77.4% of
55%) were eligible for sacubitril/valsartan. The equivalent
figure using the imputed dataset was 34.7% (77% of 48%).
Differences Between Baseline Characteristic
by Eligibility Status
In comparing eligible vs. non-eligible patients, we used sce-
nario 2 (10 mg of enalapril or equivalent daily, Table 2).
Patients eligible for sacubitril/valsartan were more likely to
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Table 1 Baseline characteristics
of patients in the Swedish Heart
Failure Registry potentially
eligible for sacubitril/valsartan
(outpatients, NYHA II-IVand EF
< 40%)
Whole cohort Patients with complete
eligibility data
Patients with incomplete
eligibility data
n = 12,866 n = 3963 n = 8903
Age (years) 72.0 ± 11.8 69.7 ± 11.9 73.0 ± 11.7
Female 3906 (30.4%) 1041 (26.3%) 2865 (32.2%)
Duration of HF
≥ 6 months
7487 (58.4%) 2180 (55.1%) 5307 (59.8%)
Systolic BP (mmHg) 125.1 ± 20.6 122.6 ± 19.72 126.3 ± 20.9
Diastolic BP (mmHg) 72.7 ± 11.6 72.2 ± 11.62 73.0 ± 11.5
Heart rate (bpm) 71.2 ± 14.2 71.0 ± 13.93 71.3 ± 14.3
BMI (kg/m2) 27.2 ± 5.3 27.3 ± 5.3 27.1 ± 5.3
NYHA functional class
II 6201 (56.3%) 2210 (55.8%) 3991 (56.6%)
III 4573 (41.5%) 1672 (42.2%) 2901 (41.1%)
IV 242 (2.2%) 81 (2.0%) 161 (2.3%)
Medical history
Hypertension 5857 (47.1%) 1723 (44.5%) 4134 (48.2%)
Type 1 diabetes
mellitus
99 (0.8%) 47 (1.2%) 52 (0.6%)
Type 2 diabetes
mellitus
2935 (22.8%) 892 (22.5%) 2043 (22.9%)
Atrial
fibrillation/flutter
5695 (44.6%) 1722 (43.6%) 3973 (45.0%)
Ischemic heart
disease
6034 (49.4%) 1758 (47.0%) 4276 (50.5%)
Valvular heart
disease
2074 (16.8%) 654 (16.7%) 1420 (16.9%)
Left bundle branch
block
2449 (23.0%) 862 (26.6%) 1587 (21.4%)
Treatments
ACE inhibitor 8586 (66.9%) 2765 (69.8%) 5821 (65.6%)
ARB 3578 (27.9%) 1172 (29.6%) 2406 (27.1%)
ACE inhibitor or
ARB
11,719
(91.1%)
3800 (95.9%) 7919 (88.9%)
Beta-blocker 11,391
(88.7%)
3736 (94.3%) 7655 (86.3%)
Diuretic 9953 (77.6%) 3041 (76.9%) 6912 (78.0%)
Digoxin 2130 (16.6%) 644 (16.3%) 1486 (16.8%)
MRA 4323 (33.8%) 1540 (39.0%) 2783 (31.4%)
Pacemaker 971 (7.6%) 282 (7.1%) 689 (7.9%)
CRT 657 (5.1%) 308 (7.8%) 349 (3.9%)
ICD 373 (2.9%) 151 (3.8%) 222 (2.5%)
Laboratory values
Hemoglobin (g/dl) 135.3 ± 16.2 136.8 ± 15.9 134.7 ± 16.2
Creatinine (μmol/l) 106.22 ± 47.5 103.90 ± 43.1 107.26 ± 49.3
Potassium (mmol/l) 4.24 ± 0.43 4.27 ± 0.42 4.23 ± 0.44
NT-proBNP (pg/ml) 2120
[933–4607]
2159 [990–4655] 2035 [813–4447]
BNP (pg/ml) 450
[154–1100]
507 [176–1186] 380 [133–894]
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, BMI body mass
index, BNP brain natriuretic peptide, CRT cardiac resynchronization therapy, HF heart failure, ICD implantable
cardioverter defibrillator, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association
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be older, have heart failure for shorter duration, higher blood
pressure, faster heart rate, and lower BMI. These patients were
also more likely to have a history of hypertension, valvular
heart disease, and atrial fibrillation and to be treated with a
diuretic or digoxin. Eligible patients had lower creatinine and
potassium and higher natriuretic peptides.
Discussion
Our results from one of the largest contemporary Breal world^
cohorts of patients with heart failure show that between 34 and
74% of outpatients with a reduced EF and persisting symp-
toms are eligible for treatment with sacubitril/valsartan, when
assessed against the main inclusion/exclusion criteria for
PARADIGM-HF. This wide range of eligibility depends on
what background dose of ACEI/ARB must be attained before
switching to sacubitril/valsartan. In this respect, some guide-
lines are more restrictive (e.g., those of the European Society
of Cardiology which require patients to be up-titrated to an
optimal dose of ACEI/ARB) whereas the regulatory labeling
for sacubitril/valsartan in both the European Union and USA
is more liberal (i.e., it does not require any specific dose of
ACEI/ARB or even prior ACEI/ARB treatment at all) [6, 7].
Consequently, there is uncertainty about how to deal with the
question of background ACEI/ARB dosing in studies of this
type [8]. As demonstrated in multiple prior studies, many
patients in the community are on lower than the Btarget^ doses
of ACEI or ARBs, recommended on the basis of randomized
controlled trials [9–11]. However, as shown in PARADIGM-
HF, and more recently in the Aliskiren Trial to Minimize
OutcomeS in Pat ien ts wi th HEar t fa i luRE tr ia l
(ATMOSPHERE) [12], many patients treated with a lower
dose of ACEI/ARB can be up-titrated to a higher dose (and
the findings in these trials are supported by prior trials adding
an ARB to an ACEI) [13, 14]. In order to enter the run-in
period in PARADIGM-HF, patients were required to have
been treated with a stable dose of an ACEI or an ARB, equiv-
alent to enalapril 10 mg/day, for at least 4 weeks before the
screening visit [5]. In the run-in, 10,513 patients were treated
with enalapril 10 mg bid for a median of 15 days. During that
period, 10.5% of patients stopped enalapril, although discon-
tinuation was due to an adverse effect or abnormal laboratory
result in only 6.2% of patients [1]. In SwedeHF, around half of
patients were not prescribed the target dose of 10 mg enalapril
twice daily or equivalent and Bongoing up-titration^ and
Bunknown^ were the commonest reasons recorded for failure
to reach target dose. Therefore, it was uncertain what denom-
inator population we should use with respect to background
ACE/ARB dose—patients on no or any dose, patients on at
least enalapril 10 mg daily (or equivalent), or only those tak-
ing enalapril 20 mg daily or greater (or equivalent)? We de-
cided to carry out all three analyses and found that the results
were similar, irrespective of denominator population (al-
though the size of the denominator population varied greatly).
Specifically, 74% of patients taking any background ACEI/
ARB dose were eligible, 75.5% of those taking ≥ 10 mg enal-
april or equivalent daily, and 77.4% of participants taking ≥
20 mg enalapril or equivalent daily, based upon analysis of
patients with complete information. Of course, since only
78% of patients were taking ≥ 10 mg enalapril or equivalent
daily and only 55% ≥ 20mg enalapril or equivalent daily, only
Fig. 1 Different eligibility scenarios tested
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58.9% of all patients were eligible for sacubitril/valsartan
based upon an enalapril dose of ≥ 10 mg or equivalent
daily (and 42.6% based on an enalapril dose of ≥ 20 mg
or equivalent daily) using the non-imputed data (these
proportions were 52% and 35%, respectively, using the
imputed dataset). The analysis using the largest denomi-
nator (potentially eligible patients, irrespective of ACEI/
ARB dose), giving an eligible proportion of the overall
population of 74%, is consistent with application of the
regulatory labeling whereas the analysis using the
smallest denominator (only patients taking ≥ 20 mg enal-
april or equivalent daily considered potentially eligible),
giving an eligible proportion of the overall population of
34%, is more consistent with the ESC guidelines [2].
It is of interest that the overall proportion of patients inel-
igible for other reasons was quite similar, irrespective of back-
ground ACEI/ARB dose. The most common reason for inel-
igibility was a low natriuretic peptide level, with between 13.7
and 16.1% of patients excluded for this reason, depending on
denominator population. However, a low natriuretic peptide
concentration was, relatively, a more common exclusion in
patients treated with a higher dose of ACEI/ARB, as might
be expected [15]. This is an interesting finding given the dis-
agreement between guidelines and the divergence between
Table 2 Baseline characteristics
of patients taking enalapril 10 mg
daily or equivalent in the Swedish
Heart Failure Registry by
eligibility status
Patients eligible for
sacubitril/valsartan
Patients not eligible
for sacubitril/valsartan
P value
n = 2340 n = 759
Age (years) 69.8 ± 11.4 65.2 ± 12.4 p < 0.0001
Female 615 (26.3%) 205 (27.0%) p = 0.69
Duration of HF ≥ 6 months 1193 (51.1%) 469 (61.9%) p < 0.0001
Systolic BP (mmHg) 126.4 ± 17.7 114.9 ± 22.2 p < 0.0001
Diastolic BP (mmHg) 74.0 ± 11.2 69.0 ± 11.9 p < 0.0001
Heart rate (bpm) 70.9 ± 14.2 68.9 ± 12.5 p = 0.0006
BMI (kg/m2) 27.3 ± 5.2 28.1 ± 5.6 p = 0.0119
NYHA functional class p = 0.10
II 1352 (57.8%) 446 (58.8%)
III 957 (40.9%) 295 (38.9%)
IV 31 (1.3%) 18 (2.4%)
Medical history
Hypertension 1094 (48.0%) 289 (38.7%) p < 0.0001
Atrial fibrillation/flutter 1051 (50.0%) 263 (34.7%) p < 0.0001
Ischemic heart disease 1025 (46.4%) 315 (44.1%) p = 0.28
Valvular heart disease 394 (17.0%) 80 (10.6%) p < 0.0001
Left bundle branch block 2449 (27.1%) 165 (26.0%) p = 0.57
Treatment
Beta-blocker 2225 (95.1%) 731 (96.3%) p = 0.16
Diuretic 1811 (77.7%) 537 (70.8%) p = 0.0001
Digoxin 416 (17.8%) 85 (11.2%) p < 0.0001
MRA 955 (40.9%) 337 (44.6%) p = 0.07
Pacemaker 155 (6.6%) 32 (4.2%) p = 0.0155
CRT 172 (7.4%) 72 (9.5%) p = 0.0576
ICD 86 (3.7%) 36 (4.7%) p = 0.1886
Laboratory values
Hemoglobin (g/dl) 137.5 ± 15.6 138.4 ± 15.8 p = 0.15
Creatinine (μmol/l) 97.0 ± 27.7 102.7 ± 44.2 p < 0.0001
Potassium (mmol/l) 4.25 ± 0.39 4.31 ± 0.47 p = 0.0008
NT-proBNP (pg/ml) 2290 [1270–4486] 451 [247–2909] p < 0.0001
BNP (pg/ml) 625 [321–1357] 93.0 [53–248] p < 0.0001
BP blood pressure, BMI body mass index, BNP brain natriuretic peptide, CRT cardiac resynchronization therapy,
HF heart failure, ICD implantable cardioverter defibrillator, MRA mineralocorticoid receptor antagonist, NYHA
New York Heart Association
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guidelines and regulatory labeling, with respect to whether
sacubitril/valsartan use should be restricted to patients with
an elevated natriuretic peptide level. A natriuretic peptide lev-
el threshold was used in PARADIGM-HF to ensure an ade-
quate event rate in the trial and the benefit of sacubitril/
valsartan over enalapril was consistent across the range of
baseline NT-proBNP concentrations in PARADIGM-HF
[16]. There is therefore no biological basis for restricting the
use of sacubitril/valsartan to a particular natriuretic peptide
level, although the absolute risk reduction with treatment is
likely to be greater in patients with a higher NT-proBNP con-
centration as such patients are at higher absolute risk [16].
The next most frequent reason for ineligibility was low
systolic blood pressure, and an opposite directional pattern
to that seen for NT-proBNP was observed, i.e., this exclusion
was less common in patients taking larger doses of ACEI/
ARB (5.9% in the ≥ 20 mg dose group, 7.9% in the ≥ 10 mg
dose group, and 9.1% in the any dose of ACEI/ARB group).
When considering the absolute proportions of patients exclud-
ed because of low blood pressure, it should be noted that our
analysis was conservative as we used a threshold of
100 mmHg which was the threshold for entry into screening
in PARADIGM-HF whereas the threshold for randomization
was 95 mmHg [5].
A similar pattern to that seen for blood pressure was ob-
served for renal dysfunction—with 0.83% of the largest
ACEI/ARB dose group ineligible for this reason compared
with 3.6% of those taking any dose of ACEI/ARB.
However, renal dysfunction, overall, was an infrequent con-
traindication to use of sacubitril/valsartan.
Hyperkalemia was an even less common contraindication
to sacubitril/valsartan, with no clear gradient across the ACEI/
ARB dose categories (1.2% in the highest dose category com-
pared with 1.4% among patients taking any dose).
The observation in PARADIGM-HF that patients random-
ized to the ARNI had a lower risk of renal impairment and
hyperkalemia during follow-up, compared with enalapril, is of
interest when thinking about switching a patient with a lower
eGFR or higher potassium level from an ACEI/ARB to
sacubitril/valsartan [1].
By definition, the patients who were identified as potential-
ly eligible for sacubitril/valsartan had higher natriuretic pep-
tide levels, higher systolic blood pressure and eGFR, as well
as a lower serum potassium concentration. Less intuitively,
eligible patients were older and more often had a history of
hypertension (both associated with a higher blood pressure
and natriuretic peptides), atrial fibrillation, and valvular dis-
ease (both associated with higher natriuretic peptides). Less
easy to explain is the finding that eligible patients were more
likely to have heart failure of shorter duration than patients not
eligible for sacubitril/valsartan.
There is one other report about eligibility for sacubitril/
valsartan from a single center in the United Kingdom. In that
study, Pellicori and colleagues identified 1396 patients with
heart failure and a reduced EF with a contemporaneous mea-
surement of NT-proBNP, of which only 379 (27%) were al-
ready on target dose of an ACEI/ARB [8]. The authors were
not able to apply the NT-proBNP inclusion criteria as in the
trial (i.e., ≥ 600 pg/ml or, in patients hospitalized for heart
failure in the preceding 12 months, ≥ 400 pg/ml), because
timing of hospitalization was not known. However, using a
400 pg/ml threshold, 66 of 379 patients (17.4%) would have
been ineligible, similar to the 16.1% excluded for this reason
in our equivalent population [8]. Low blood pressure and
eGFR and high potassium were less common causes of inel-
igibility for treatment with sacubitril/valsartan, similar to what
we found in SwedeHF.
There are also two reports about use of sacubitril/
valsartan from the Get With the Guidelines-Heart Failure
(GWTG-HF) initiative in the USA. One report examined
eligibility for treatment in registry patients hospitalized
with HF-REF between January 2011 and December 2013.
Overall, 69% met FDA labeling criteria for sacubitril/
valsartan and 55% of these individuals met PARADIGM-
HF-like eligibility criteria (38% of patients overall) [17].
Although this was a study of hospitalized patients, the pro-
portions eligible were similar to those identified in our anal-
yses of ambulatory patients in a European country. The
other study examined actual sacubitril/valsartan prescribing
among 21,078 discharges from 347 hospitals [18]. This
treatment was prescribed in only 495 cases (equivalent to
3.6% of discharges from January to June 2016). This much
lower rate of actual use (as opposed to potential use) may
reflect the difference between the ambulatory patients en-
rolled in PARADIGM-HF and the hospitalized patients in
GWTG-HF, as well as barriers to prescribing [17].
Limitations We used only the most recent patient encounter
recorded in SwedeHF. Eligibility/ineligibility for sacubitril/
valsartan is not fixed and is likely to change over time
reflecting the fluctuating nature of heart failure.
Consideration of a patient for sacubitril/valsartan, as with
any drug or device therapy, should be re-evaluated several
times during the patient journey. For example, implantation
of cardiac resynchronization therapy could improve blood
pressure or renal function in a patient. The PARADIGM-HF
EF inclusion criterion (≤ 40%) did not exactly match the EF
categories recorded in SwedeHF (< 30%, 30–39%, 40–49%,
and > 50%).
ConclusionsBetween 34 and 74% of patients with heart failure
and reduced EF are eligible for treatment with sacubitril/
valsartan, depending on the background dose of ACEI/ARB
deemed necessary before switching therapy. The other main
inclusion/exclusion criteria used in PARADIGM-HF render
around 20 to 30% of patients ineligible for sacubitril/
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valsartan and this proportion does not differ much by back-
ground dose of ACEI/ARB.
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